Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, Lindwurmstrasse 2a, 80336, Munich, Germany.
German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the University Hospital of the LMU, Munich, Germany.
BioDrugs. 2024 Sep;38(5):611-637. doi: 10.1007/s40259-024-00669-y. Epub 2024 Jul 30.
Chimeric antigen receptor T cell therapy has been established in the treatment of various B cell malignancies. However, translating this therapeutic effect to treat solid tumors has been challenging because of their inter-tumoral as well as intratumoral heterogeneity and immunosuppressive microenvironment. Local interventions, such as surgery, radiotherapy, local ablation, and locoregional drug delivery, can enhance chimeric antigen receptor T cell therapy in solid tumors by improving tumor infiltration and reducing systemic toxicities. Additionally, ablation and radiotherapy have proven to (re-)activate systemic immune responses via abscopal effects and reprogram the tumor microenvironment on a physical, cellular, and chemical level. This review highlights the potential synergy of the combined approaches to overcome barriers of chimeric antigen receptor T cell therapy and summarizes recent studies that may pave the way for new treatment regimens.
嵌合抗原受体 T 细胞疗法已被确立用于治疗各种 B 细胞恶性肿瘤。然而,由于实体肿瘤存在肿瘤间和肿瘤内异质性以及免疫抑制微环境,将这种治疗效果转化为治疗实体肿瘤具有挑战性。局部干预,如手术、放疗、局部消融和局部药物输送,可以通过改善肿瘤浸润和降低全身毒性来增强实体肿瘤中的嵌合抗原受体 T 细胞疗法。此外,消融和放疗已被证明通过远隔效应(abscopal effects)重新激活全身免疫反应,并在物理、细胞和化学水平上重新编程肿瘤微环境。这篇综述强调了联合治疗方法的潜在协同作用,以克服嵌合抗原受体 T 细胞治疗的障碍,并总结了可能为新的治疗方案铺平道路的最近研究。